0
Abstract: Slide Presentations |

THE SAFETY OF DROTRECOGIN ALFA (ACTIVATED): INDEPTH DATA ANALYSIS SUGGESTS SURVIVAL BENEFIT INDEPENDENT OF SERIOUS ADVERSE EVENT OCCURRENCES FREE TO VIEW

Robert Levine, MD*; Stephen Lowry, MD; Jean-Francois Dhainaut, MD; Pierre-Francois Laterre, MD; Greg Beilman, MD; I. A. Fein, MD; Luiz Poli de Figueiredo, MD; Jonathan Janes; David Nelson, MS; Joan Bailey, BNS; Frank Booth, MD; Michael Cobas Meyer, MD
Author and Funding Information

University of Texas School of Medicine, Houston, TX


Chest


Chest. 2005;128(4_MeetingAbstracts):221S-a-222S. doi:10.1378/chest.128.4_MeetingAbstracts.221S-a
Text Size: A A A
Published online

Abstract

PURPOSE:  To better understand treatment risks and benefits of drotrecogin alfa (activated) (DrotAA), a clinical evaluation committee evaluated all serious adverse events (SAEs), occurring across five clinical trials [conducted by a single sponsor (Eli Lilly and Company) and integrated into single database, INDEPTH (4459 patients)] in patients with severe sepsis.

METHODS:  We examined all SAEs which occurred during infusion (n=277) from 1231 placebo and 3228 DrotAA patients. Investigators were blinded to treatment assignment.

RESULTS:  Total SAE rates were similar. More bleeding but fewer non-bleeding SAEs occurred in patients receiving DrotAA. Approximately half of the SAEs during the 28-day study period were reported at a time when DrotAA (and also placebo) was not being infused and are considered likely unrelated, given the known short half-life of the drug. (See Table 1) SAEs occurred with similar frequency in both treatment arms and notably 93.8% of the DrotAA and 93.7% of the placebo treated patients did not experience an SAE during the infusion. Mortality was still lower in DrotAA treated patients compared to placebo in patients experiencing a bleeding or non-bleeding SAE. (See Table 1).

CONCLUSION:  Although DrotAA is associated with an increased bleeding risk, it was also associated with fewer thrombotic events and the overall rate of SAEs was similar. Mortality was lower in DrotAA treated patients even in the presence of a bleeding or a non-bleeding event. Adjustment for the use of multiple studies with propensity scores did not affect these conclusions.

CLINICAL IMPLICATIONS:  Benefit of treatment with DrotAA outweights the risks associated with adverse events and improves survival. Table 1SAEs During Infusion PeriodDrotAAPlacebop Value**All SAEs199 (6.16%)78 (6.34%)0.832Non Bleeding Events113 (3.50%)72 (5.85%)<0.001Arterial Thrombotic Events*26 (0.81%)22 (1.79%).0045Bleeding Events101 (3.13%)9 (0.73%)<0.001CNS Bleeding15 (0.46)1(0.08)0.087****

MI, stroke without hemorrhage, other arterial thrombotic events

DISCLOSURE:  Robert Levine, Consultant fee, speaker bureau, advisory committee, etc. Advisory panel fee.

10:30 AM - 12:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543